Dose-optimised recombinant human thrombopoietin <i>versus</i> eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study).

EClinicalMedicine · 2025 · PMC12396493 · PMID 40896456

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

There was a decreasing trend in the proportion of patients with bleeding from baseline to week 6 in both groups.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Dose-optimised recombinant human thrombopoietin &lt;i&gt;versus&lt;/i&gt; eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study).

The sentences

Dose-optimised recombinant human thrombopoietin <i>versus</i> eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study).